Clinical Trials
11 trialsNCT07281833 2026-02-27
CAPIcorn
West German Study Group
Phase 3 Recruiting
NCT03801369 2026-02-25
AMTEC IIT: Phase 2 Multiarm Study in TNBC
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT05826964 2026-01-13
Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer
University of Miami
Phase 2 Active not recruiting
NCT02208375 2025-12-31
mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT06613516 2025-12-24
CaptAin
Imperial College London
Phase 2 Withdrawn
NCT02423603 2025-03-10
PAKT
Queen Mary University of London
Phase 2 Completed
NCT02299999 2025-01-15
SAFIR02_Breast
UNICANCER
Phase 2 Active not recruiting
NCT05720260 2024-06-10
Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC
National Taiwan University Hospital
Phase 2 Recruiting
NCT03310541 2023-05-06
AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT03182634 2019-01-22
plasmaMATCH
Institute of Cancer Research, United Kingdom
Phase 2 Unknown
NCT02077569 2017-05-04
STAKT
University of Nottingham
Phase 2 Completed